Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong

July 31, 2018

Andrew Armstrong and Alicia Morgans, discuss the PROPHECY trial, a prospective trial of circulating tumor cells, evaluating two current assays: the EPIC AR-V7 Nuclear Protein CTC and the Hopkins AR-V7 Adnatest. The conversation evolves to a discussion of the data from Armstrong's recent work shared at the 2018 ASCO GU meeting: measuring osteomimicry in three levels: RNA, DNA, and protein, potentially explaining how Radium 223 works.  In addition, this study provides a novel finding in that CTCs provide a viable compartment of surviving cells in the circulation.  

Andrew J. Armstrong MD MSc, Full Professor of Medicine at Duke University, Durham, NC.  He is a clinical and translational researcher focused on drug development and biomarker studies in prostate and kidney cancer. This research includes prognostic and predictive biomarkers, circulating tumor cell biology, and how cancer spreads (metastasis). He oversees multiple clinical trials of new therapies for patients ranging from new hormonal and chemotherapies to new immunotherapies and molecularly targeted agents. Additionally, Dr. Armstrong is an Associate Professor of Medicine, Associate Professor in Pharmacology and Cancer Biology and Associate Professor in Surgery

Alicia Morgans, MD, MPH

Studies Referenced in this Interview:
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England Journal of Medicine 2014;371:1028-38.

Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

PROPHECY - A Prospective Trial of Circulating Tumor Cell AR-V7 Detection in mCRPC with Abiraterone or Enzalutamide